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Abstract
Background: Dengue is now a leading cause of morbidity and mortality throughout the tropics. We conducted
the first ex vivo study of dengue fever (DF) in African patients infected during the first Gabonese dengue virus 2
(DENV-2) outbreak in 2007, in order to investigate cytokine production, including the antiviral cytokine IFN-a,
reported to be a potent inhibitor of DENV replication in vitro.
Methods: Levels of 50 cytokines, chemokines and growth factors were measured in plasma from 36 patients with
DENV-2 infection, and in uninfected controls, using Luminex multiplex technology. The results were interpreted
according to the day of sampling after symptom onset. PBMC from six patients were also studied for T lymphocyte
cell surface marker expression by flow cytometry.
Results: Acute DENV-2 infection elicited high levels of several pro-inflammatory cytokines (IL-6 and IL-17),
chemokines (MIF, RANTES, IP-10 and MCP-1) and growth factors (G-CSF, GM-CSF and VEGF-A). We also observed
high levels of IFN-a for the first time in adult DF patients, and CD4+ and CD8+ T cell activation at symptom onset.
Conclusion: Acute DENV-2 infection in African patients elicits a strong innate response involving IFN-a production,
as well as an adaptive immune response.
Background
Dengue virus (DENV), of which four serotypes have
been identified (DENV-1 through DENV-4), is a single-
stranded positive-sense RNA virus belonging to the
genus Flavivirus of the Flaviviridae family. DENV gen-
erally causes an acute self-limited illness known as clas-
sic dengue fever (DF), lasting 5-7 days [1]. Symptoms
include high fever, headache, retro-orbital headache,
myalgia, arthralgia, abdominal pain, nausea and vomit-
ing. A minority of patients (less than 3%) develop den-
gue hemorrhagic fever (DHF) or dengue shock
syndrome (DSS), the most severe form. Dengue is the
most frequent human vector-borne viral disease. Until
the 1960s, DENV was mainly restricted to tropical and
subtropical regions, especially south-east Asia, but it has
now spread to South Asia, South and Central America,
the Caribbean, and Africa. DENV is transmitted by peri-
domestic female mosquitoes of the genus Aedes [2]. Ae.
aegyptii, present in most endemic regions [3], was con-
sidered to be the main vector of DENV. Nevertheless,
Ae. albopictus was suspected of being the main vector
of DENV during major epidemics [4] and was shown to
be the only vector during simultaneous outbreaks of chi-
kungunya and DENV-2 infection occurring in Gabon in
2007 [5]. Two-fifths of the world population are at risk,
and an estimated 50 to 100 million cases of DF occur
each year worldwide. About 500 000 people develop
DHF and about 20 000 deaths occur, mainly among
children under 15 years of age. The incidence of DENV
infection has risen more than 30-fold in the past 50
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impact of this disease, there is currently no vaccine and
no specific treatment.
Numerous studies have explored the cytokine
response to DENV. The cellular IFN system is the main-
stay of host defenses during the first days of infection, a
phase during which the intensity of viral replication
determines clinical outcome [8]. In vitro,D E N Vi n f e c -
tion of human cells can be inhibited by pretreatment
with IFN-a/b and IFN-g [9], which inhibit translation of
the viral RNA input strand [10]. Interestingly, DENV-2-
infected monocyte-derived dendritic cells in vitro fail to
prime T cells, due to the lack of IFN-a/b produced in
those cells after infection [11]. The importance of the
IFN-a response in vivo is illustrated by the increased
lethality of mouse-adapted DENV-2 virus when adminis-
tered by intraperitoneal injection to IFN-a/b and g
receptor knockout mice [12]. Little is known of human
plasma IFN-a concentrations during the acute phase of
the illness. One study showed elevated IFN-a plasma
levels shortly after symptom onset in DF children [13].
Proinflammatory cytokines such as TNF-a,I F N - g,I l - 6 ,
Il-18 and MIF are also known to be involved during the
acute phase of the illness [14-18], and many chemokines
involved in leukocyte recruitment to sites of infection,
s u c ha sI L - 8 ,I P - 1 0a n dM C P - 1 ,a r ep r o d u c e dd u r i n g
inflammation [19-23]. Primary cultured human mono-
cytes infected by DENV-2 produce proinflammatory
cytokines such as IFN-a,T N F - a and IL-6 [24,25], and
PBMC infected by DENV-2 in vitro produce pro-
inflammatory cytokines and other soluble mediators,
including TNF-a,I F N - g, IL-2, Il-4, IL-5, Il-6 and Il-10
[26]. Evidence of T cell activation has also been
observed, with a rise in the percentage of CD4+ and
CD8+ T lymphocytes expressing CD69, an early activa-
tion marker, reported in children with acute DF [27].
In severe forms (DHF/DSS), after a normal acute
phase, capillary permeability increases abruptly and the
resulting plasma leakage can lead to circulatory shock
and death. The severity of DENV infection seems to be
due more to disproportionate inflammatory cytokine
production than to direct viral effects [28-30]. Antibody-
dependent enhancement (ADE) has also been impli-
cated, based on observations that re-infection by a
different viral serotype increases the risk of severe den-
gue [31]. In this case, rapid activation of cross-reactive
DENV-specific memory T cells generated during
primary DENV infection appears to trigger strong produc-
tion of proinflammatory cytokines such as IFN-g,T N F - a
and Il-6, that can directly damage vascular endothelial
cells, further resulting in plasma leakage [29,32]. DENV-
specific T cells may have a dual role, both helping to clear
the virus and causing bystander tissue damage. Finally,
DENV, like many other viruses, has evolved molecular
mechanisms to circumvent IFN-mediated responses [33]
and expression of DENV non-structural proteins (NS5B,
NS4B, NS4A, NS2A) by infected cells has been shown to
disrupt the IFN-a/b signalling pathway [34-38].
Most ex vivo studies have involved patients in ende-
mic regions of Asia and America, and the serotype was
often not clearly identified. The incidence of DENV has
increased in Africa since 2000, especially in central
Africa, indicating a change in DENV epidemiology in
this region [5,39,40]. We conducted the first ex vivo
study of African DF patients infected during the first
Gabonese DENV outbreak of 2007. The patients had
probably never encountered DENV previously, and were
therefore unlikely to have developed specific immunity.
In order to investigate cytokine expression, and espe-
cially the role of IFN-a, during the acute phase of
DENV infection in adults, we used Luminex multiplex
technology to measure the levels of 50 soluble factors,
including cytokines never or rarely studied in this set-
ting. We also explored T lymphocyte responses during
the first days after symptom onset.
Methods
Patients and samples
Between March and August 2007, simultaneous chikun-
gunya and dengue outbreaks occurred in Gabon, initially
in the capital city Libreville [5]. Outbreaks subsequently
occurred in several small towns along the route to
northern Gabon and Cameroon, causing about 20,000
cases. During the course of the outbreak, 773 blood
samples were collected during the first week after symp-
tom onset from febrile patients who visited healthcare
centers in Libreville and other Gabonese towns. The
patients’ demographic characteristics, clinical features
and symptom duration were recorded. Blood was drawn
into EDTA tubes (Becton Dickinson) and transported
on ice daily to the virology laboratory of Libreville
faculty of medicine. The tubes were centrifuged for 10
min at 2000 g at room temperature, and plasma was
recovered, aliquoted and stored at -80°C. Peripheral
blood mononuclear cells (PBMC) were isolated by stan-
dard Histopaque density centrifugation if sufficient
blood was available. PBMC were resuspended in fetal
calf serum (FCS) (Invitrogen) with 10% dimethyl sulfox-
ide (Merck) in Cryovials (Nunc), kept at -80°C over-
night, then transferred to liquid nitrogen and
transported weekly to the Franceville International Med-
ical Research Center (CIRMF).
Samples were tested at CIRMF for DENV and chikun-
gunya virus RNA by using TaqMan quantitative reverse
transcription-PCR (qRT-PCR) technology. Among the
773 patients, 275 (35.6%) and 54 (7.0%) were positive
for chikungunya virus and DENV, respectively. Using a
dengue serotype-specific qRT-PCR assay, we showed
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(DENV-2) [5]. A quantified synthetic DENV RNA tran-
script kindly provided by the University of the Mediter-
ranean (Prof. X. De Lamballerie) was used as standard
for the quantification of DENV-2 RNA in positive sam-
ples. All amplifications were performed in duplicate.
No severe cases of dengue infection (DHF, DSS) were
observed during this epidemic. The DENV-2-positive
samples were negative for various arbovirus RNA gen-
omes (Chikungunya, West Nile, yellow fever and Rift
Valley fever viruses), as tested by Taqman qRT-PCR,
and also for West-Nile virus antibodies, as tested with
an ELISA method.
Thirty control plasma samples were randomly selected
among 4349 samples collected from healthy individuals
throughout Gabon during a previous study [41]. These
individuals were themselves randomly selected among
the Gabonese rural population, excluding children and
elderly persons (more than 65 years).
PBMC from five randomly selected healthy volunteers
(40% male; mean age 29 years, range 25-32 years) were
also used as controls.
Ethical considerations
The study was approved by the Gabonese Ministry of
Health (authorization N°000006 MSP/SG), and written
informed consent was granted by all the patients and
healthy controls.
Multiplex analysis
Concentrations of 50 cytokines, chemokines and growth
factors were measured in plasma by means of Luminex
technology (Bio-Rad). Two kits – the Bio-plex human
cytokine 27-plex assay and the Bio-plex human cytokine
23-plex assay (Bio-Rad) – were used, as recommended
by the manufacturer. The following cytokines were mea-
sured: interleukin-1b (IL-1b), IL-1 receptor antagonist
(IL-1Ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10,
IL-12p70, IL-13, IL-15, IL-17, eotaxin, basic fibroblast
growth factor (FGF-basic), granulocyte colony-stimulat-
ing factor (G-CSF), granulocyte macrophage colony-
stimulating factor (GM-CSF), IFN-g, IP-10, monocyte
chemoattractant protein 1 (MCP-1), macrophage inflam-
matory protein-1a (MIP-1a), MIP-1b, platelet-derived
growth factor-bb (PDGF-bb), regulated-on-activation
normal T-cell expressed and secreted (RANTES), tumor
necrosis factor-a (TNF-a), and vascular endothelial
growth factor (VEGF) in the 27-plex assay; and Il-1a,
IL-2Ra, Il-3, Il-12p40, IL-16, IL-18, CTACK (or
CCL27), GRO-alpha (or CXCL1), hepatocyte growth
factor (HGF), intracellular adhesion molecule 1 (ICAM-
1), IFN-a2, leukemia inhibitory factor (LIF), MCP-3 (or
CCL7), macrophage colony-stimulating factor (M-CSF),
monokine induced by interferon-gamma (MIG or
CXCL9), nerve growth factor-b (NGF-b), stem cell fac-
tor (SCF), stem cell growth factor b (SCGF-b), SDF-1a
(or CXCL12), tumor necrosis factor beta (TNF-b),
tumor necrosis factor beta (TRAIL) and VCAM-1 in the
23-plex assay. Briefly, 25 μL of plasma was diluted 1:4 in
Bioplex human sample diluent and incubated with anti-
cytokine antibody-coupled beads for one hour at room
temperature. Between each step the complexes were
washed three times in wash buffer (Bio-Rad), using a
vacuum manifold. The beads were then incubated with
a biotinylated detector antibody for one hour before
incubation with streptavidin-phycoerythrin for 30 min-
utes. Finally, the complexes were resuspended in 125 μL
of detection buffer and 200 beads were counted with a
Luminex 200™ device (Bio-Rad). Final concentrations
were calculated from the mean fluorescence intensity
and expressed in pg/mL.
Flow cytometry
Patient and control PBMC were thawed, washed thrice
in RPMI 1640 with 1% penicillin/streptomycin, and
resuspended at a final density of 2 × 10
6 cells/mL in
RPMI with 10% FCS and 1% penicillin/streptomycin for
18 hours at 37°C. Prior to staining, cells were washed in
RPMI then distributed at a final density of 1 × 10
6 cells/
mL in 0.1 mL of Isoflow (Beckman Coulter) in three
tubes containing monoclonal antibodies, as follows: tube
1: CD3-FITC, CD4-PE, CD69-PC5 and CD8-PC7; tube
2: CD3-FITC, CD4-PE, HLADR-PC5 and CD8-PC7;
tube 3 CD3-FITC, CD95-PE, CD4-PC5 and CD8-PC7
(Beckman Coulter). After staining for 20 minutes at
room temperature and the addition of 200 μLo fI s o -
flow, 100 000 events were captured on a FC500 cyt-
ometer (Beckman Coulter) and analyzed with CXP
software (Beckman Coulter).
Statistical analysis
Student’s t test was used to compare normally distribu-
ted cytokine concentrations between the patients and
controls, while the Mann Whitney Wilcoxon test was
used for non normally distributed data. Normality was
tested with the Shapiro-Wilk test. P values below 0.01
were considered to indicate significant differences (to
take account of multitesting for the groups of cytokines,
the type I risk was reduced from 0.05 to 0.01 using Bon-
ferroni correction). STATA 10.0 (College Station, Texas
USA) and SavGIS 9.05 software (IRD, France) was used
for all analyses.
Results
DENV-2 viral load
Viral load (VL) was measured in plasma by real-time
quantitative PCR in DENV-2-infected patients. Mean
VL was 1.2 × 10
6 ±4 . 4×1 0
1 cDNA copies/mL (2.7 ×
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4 to 5.1 × 10
7 cDNA copies/mL). VL did not vary sig-
nificantly with age, sex or the day of sampling after
symptom onset (data not shown).
Plasma cytokine, chemokine and growth factor levels
Soluble factor concentrations were measured in 36
DENV-2-infected patients (40% male; mean age 31
years, range 18-66 years) from whom single blood sam-
ples were collected between D0 and D11 after symptom
onset, and 30 randomly selected uninfected and healthy
individuals (60% male; mean age 47 years, range 30-65
years). Levels in the patients’ samples were further
interpreted according to the time (in days) after symp-
tom onset (D0). One patient was sampled on day 0,
s e v e no nD 1 ,t e no nD 2 ,n i n eo nD 3 ,t w oo nD 4 ,t h r e e
on day 5, two on D7 and two on D11. The 23-plex
assay could not be applied to samples obtained from
four patients on D7 and D8, owing to insufficient sam-
ple volume.
Relative to the controls, the patients had significantly
elevated levels (p < 0.01) of growth factors (G-CSF,
GM-CSF and VEGF-A), pro-inflammatory and antiviral
cytokines (IL-6, Il-17 and IFN-a2), anti-inflammatory
cytokines (IL-1Ra, IL-2ra and Il-13), chemokines (Il-16,
MCP-1, IP-10, SDF-1a, MIF and RANTES), and cyto-
kines associated with adaptive responses (Il-7, Il-12p40
and IFN-g) (Figure 1, Figure 2, Figure 3 and Figure 4).
During the first days of symptoms, levels of IL-1Ra,
IL-2ra, Il-6, IL-7, IL-12p40, IL-13, IFN-a2, VEGF-A and
SDF-1a were significantly higher in the patients than in
the controls (Figure 1, Figure 2, Figure 3 and Figure 4).
IFN-a2 levels exceeded 400 pg/mL throughout the
acute phase in 20/26 patients (controls: 217 ± 28 pg/
mL). Il-16 and Il-17 levels were significantly elevated
from D2 to D3 (Figure 1), and G-CSF and GM-CSF
levels from D1 to D5 and D1 to D11, respectively (Fig-
ure 4). IFN-g was elevated (>200 pg/mL) in the only
patient sampled on D0 (p < 0.01), and in most of the
patients sampled on D1 (5/8) and D2 (6/10; p < 0.01)
(Figure 3). MIF was elevated on D1, MCP-1 on D2, and
IP-10 on D5 (p < 0.01) (Figure 1).
Levels of ICAM-1, VCAM-1 and RANTES were above
the working range of the assay in the patients but not in
the controls (data not shown).
Levels of IL-3, TNF-b, Il-1a, eotaxin, CTACK, M-CSF,
SCF and b-NGF were lower in the patients than in the
controls (Figure 5).
There were no significant differences between the
patients and controls regarding the concentrations of
IL-1b, Il-4, IL-5, IL-8, IL-9, IL-10, IL-15, IL-18, TNF-a,
MIP-1a,M I P - 1 b, MCP-3, Il-12p70, FGF-basic, HGF,
PDGF-bb, LIF, MIG, SCGF-b or TRAIL (see Additional
file 1).
Flow cytometry
PBMC from 6 patients (34% male; mean age 34 years,
range 20-47 years) and 5 controls were studied for T cell
surface markers (Table 1). The mean age and the male/
female gender ratio were not different between the two
groups (p > 0.7; data not shown). Positive gating for lym-
phocytes based on forward and side scatter was followed
by CD3+ CD4+ and CD3+ CD8+ gating. Statistical tests
were not used, owing to the limited number of patients
(one patient on D0, one patient on D1, two patients on
D2, two patients on D3). The percentage of CD3+ CD8+
T cells was higher on D0 in the patients than in the con-
trols (41% versus 16%), while the percentage of CD3+
CD4+ lymphocytes was stable during the acute phase.
Expression of the activation markers CD69 and HLA-
DR was further analyzed. CD3+ CD4+ T cells reached a
maximum activation on D0 and D1, as shown by a peak
in CD69 expression on D1 (29% versus 9% in controls)
and in HLA-DR expression on D0 (13% versus 4% in
controls) and D1 (12% versus 4% in controls). The per-
centage of CD3+ CD8+ CD69+ lymphocytes was highest
on D1 (51% versus 23% in controls), while the percen-
tage of CD3+ CD8+ HLA-DR+ lymphocytes was highest
on D0 (38% versus 8% in controls).
CD95 expression on CD3+ CD4+ T lymphocytes was
elevated in all the patients on D0 to D3 (31% on D0,
25% on D1 and D2, and 39% on D3, versus 2% in the
controls). In contrast, percentage of CD3+ CD8+ CD95
+ T lymphocytes was lower on D0 and D1 (3% on D0
and 2% on D1) than in the controls (11%), while no dif-
ference was observed on D2 or D3.
Discussion
This is the first study of the innate immune response to
DENV in an African population. One of the most signif-
icant results of this study is the sustained elevated levels
of IFN-a2 throughout the acute phase of the illness in
all DENV-2-infected patients. IFN-a, mainly produced
by dendritic cells and macrophages [42], is a first line of
host defense, limiting viral replication. In addition to its
antiviral affects, IFN-a induces the expression of major
histocompatibility complex class I molecules, enhancing
antigen presentation and thereby triggering the acquired
immune response. IFN also induces antigen-specific
CD8+ cell responses and chemokine production, leading
to activation of lymphocytes and monocytes and their
recruitment to sites of inflammation [43]. A previous
study of Thai children aged 5-14 years with DF showed
elevated IFN-a levels only on D1 and D3 after fever
onset [13]. This slight discrepancy with our findings
might be due to immunological immaturity, detection of
different IFN-a subtypes [44], infection by different
DENV serotypes, assay sensitivity and specificity, or
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firm, in DENV-2-infected adults, the potential role of
IFN-a in DENV infection, as shown in vitro and in ani-
mal studies [9,10,12]. Studies exploring the relationship
between viral load and the clinical severity of dengue
infection have given conflicting results [8,45-47]. We
found no correlation between virus load (measured by
qRT-PCR) and IFN-a levels (r
2 < 0.4; data not shown).
This could be explained by the absence of severe cases
of DENV infection, the consistently high IFN-a levels in
all DENV-2 infected patients, the small size of the study
population, and infection by a different DENV serotype.
A more recent study in Taiwan suggested that patients
with secondary DEN-2 infections mount an altered
immune response with lower IFN-a levels, 3-7 days
after symptom onset, associated with the onset of DHF
0
50
100
CTL D0 D1 D2 D3 D4 D5 D7 D11
IL-6














0
100
200
300
CTL D0 D1 D2 D3 D4 D5 D7 D11
IL-17








0
100
200
300
400
CTL D0 D1 D2 D3 D4 D5 D7 D11
MCP-1


0
10000
20000
30000
CTL D0 D1 D2 D3 D4 D5
IL-16

 

0
500
1000
1500
CTL D0 D1 D2 D3 D4 D5
SDF1-α

 
 
 


 IP-10
0
10000
20000
30000
CTL D0 D1 D2 D3 D4 D5 D7 D11


0
20000
40000
60000
CTL D0 D1 D2 D3 D4 D5
MIF


Figure 1 Pro-inflammatory cytokines and chemokines upregulated in plasma of DF patients . Levels are expressed in pg/mL, according to
the day of sampling after symptom onset (*p < 0.01). Mean control (CTL) levels are shown in red. The vertical bars represent the standard
deviation. One patient was sampled on day 0, seven on D1, ten on D2, nine on D3, two on D4, three on day 5, two on D7 and two on D11.
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Page 5 of 11[48]. This suggests that the earlier proinflammatory
reaction associated with IFN-a m a yb ec r i t i c a lf o rt h e
pathogenesis of secondary DENV-2 infections. Interest-
ingly, in another study, IFN-a levels fell after the peak
in viremia, one day before defervescence in Thai
children aged 6 months to 14 years with secondary
DENV-3 infection [46]. In our study, more than 85% of
DENV-2 infected patients (data not shown) still had
IL-2rα
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Figure 2 Anti-inflammatory cytokines upregulated in plasma of DF patients . Levels are expressed in pg/mL, according to the day of
sampling after symptom onset (*p < 0.01). Mean control (CTL) levels are shown in red. The vertical bars represent the standard deviation. One
patient was sampled on day 0, seven on D1, ten on D2, nine on D3, two on D4, three on day 5, two on D7 and two on D11.
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Figure 3 Cytokines upregulated in plasma of DF patients. Levels are expressed in pg/mL, according to the day of sampling after symptom
onset (*p < 0.01). Mean control (CTL) levels are shown in red. The vertical bars represent the standard deviation. One patient was sampled on
day 0, seven on D1, ten on D2, nine on D3, two on D4, three on day 5, two on D7 and two on D11.
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persisted throughout the acute phase. IFN-a levels
could not be measured on the day of defervescence.
T h ei n n a t er e s p o n s et oD E N Vi nt h e s ep a t i e n t sw a s
also characterized by the production of proinflammatory
chemokines and growth factors (Il-6, RANTES, IP-10,
MCP-1, G-CSF, GM-CSF and VEGF-A). One originality
of this study is that, contrary to previous reports, soluble
factors level were measured throughout the acute phase
[14,18,21-23,49,50]. Chemokines are produced by acti-
vated monocytes and macrophages, which are known
DENV target cells [51]. Chemokines orchestrate leuko-
cyte recruitment to sites of viral infection and play a key
role in inflammatory responses [52]. Growth factors
such as G-CSF and GM-CSF may contribute to the
differentiation of myeloid progenitors and resting mono-
cytes (GM-CSF) [53] or granulocyte progenitors
(G-CSF) [54]. VEGF, a factor produced by many cells,
including macrophages [55] and endothelial cells [56], is
the most potent permeability-enhancing cytokine and
seems to play an important role in the plasma leakage
observed in DHF [57]. Interestingly, we observed ele-
vated IL-17 levels during the first days after symptom
onset. Il-17 is the signature cytokine of the newly
described T helper 17 (Th-17) cell population [58] and
has been proposed as the founding member of a new
subclass of proinflammatory cytokines involved in
dengue, eliciting cytokines such as Il-6, Il-8, MCP-1,
GRO-a and TNF-a [59]. Levels of the proinflammatory
cytokine TNF-a were not altered, in keeping with pre-
vious studies [15,18,60]. In contrast, two studies have
shown TNF-a elevation in patients in Venezuela [14]
and India [61]. Differences in population characteristics
or prior immune status may explain this discrepancy
with our results.
We also observed elevated levels of the anti-inflam-
matory cytokines IL-2Ra,I L - 1 R aa n dI L - 1 3i nm o s to f
our patients, throughout the acute phase. It is gener-
ally assumed that circulating IL-1Ra diffuses into
tissues and influences the local Il-1Ra:Il-1 ratio, modu-
lating a variety of Il-1-related immune and inflamma-
tory responses [62]. The elevated IL-13 levels observed
here are in keeping with previous findings [17]. Il-13 is
produced by T lymphocytes and inhibits the produc-
tion of pro-inflammatory cytokines by activated mono-
cytes [63]. High levels of these anti-inflammatory
cytokines may contribute to limiting bystander tissue
damage that could otherwise occur during prolonged
inflammation.
IFN-g and Il-7 promote adaptive immunity [64-66],
and the elevated levels observed here therefore suggest
the involvement of cellular responses during DENV
infection. Levels of IFN-g, which is mainly produced
by activated professional antigen-presenting cells,
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Figure 4 Plasma growth factors upregulated in plasma of DF patients . Levels are expressed in pg/mL, according to the day of sampling
after symptom onset (*p < 0.01). Mean control (CTL) levels are shown in red. The vertical bars represent the standard deviation. One patient was
sampled on day 0, seven on D1, ten on D2, nine on D3, two on D4, three on day 5, two on D7 and two on D11.
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Figure 5 Pro-inflammatory cytokines and growth factors downregulated in plasma of DF patients . Levels are expressed in pg/mL,
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Page 8 of 11T lymphocytes and NK cells [64], also point to T cell
activation. High levels of IFN-g were also observed in
previous studies [15,18,61,67,68]. These results are
supported by the increased expression of activation
markers (CD69 and HLA-DR) on CD4+ and CD8+ T
cells at symptom onset. A previous study showed an
increase in the percentage of CD69-expressing CD4+
and CD8+ T cells in Thai children within 72 h after
fever onset [27].
Surprisingly, we observed CD95 upregulation on CD3
+ CD4+ T cells during the first four days after symptom
onset (16-40% of cells, compared to 2% in controls). In
contrast, no differences in CD95 expression on CD3+
CD8+ T lymphocytes were observed. To our knowledge,
this is the first study of the percentage of CD3+ CD4+
and CD8+ CD95+ T lymphocytes during the acute
phase of DF. In a previous study, TUNEL staining of
fragmented DNA showed that large numbers of PBMC
(mostly CD8+ T lymphocytes) were undergoing apopto-
sis around the time of defervescence in DENV-1- or
DENV-3-infected Thai children [69], and the degree of
apoptosis correlated with disease severity and with the
risk of DHF. After the virus has been cleared (after 1 to
7 days) and defervescence occurs [8], CD95/CD95
ligand-mediated apoptosis may be one mechanism pro-
moting the death of activated T cells. However, owing
to the small size of our panel (6 patients), larger investi-
gations are required to further explore apoptosis of T
lymphocyte subpopulations during dengue infection.
Conclusions
This is the first study of the immune response to den-
gue virus in African patients, who had probably never
previously encountered this pathogen. We observed
high IFN-a plasma levels during the acute phase, sup-
porting the results of in vitro and animal studies.
Furthermore, we confirm in African patients that
DENV-2 infection induces a strong innate response
involving numerous pro-inflammatory factors, as well as
an adaptive immune response involving CD4 and CD8
T cell activation. These findings raise the possibility that
IFN-a administration might prevent progression to
severe forms of dengue fever.
Additional material
Additional file 1: Cytokines, chemokines and growth factors
unchanged in DF patients compared to controls (p > 0.05)
throughout the acute phase. Levels are expressed in pg/mL, according
to the day of sampling after symptom onset. Mean control (CTL) levels
are shown in red. The vertical bars represent the standard deviation. One
patient was sampled on day 0, seven on D1, ten on D2, nine on D3, two
on D4, three on day 5, two on D7 and two on D11.
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